Coya Therapeutics Files 8-K on Shareholder Votes

Ticker: COYA · Form: 8-K · Filed: Jun 26, 2025 · CIK: 1835022

Coya Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyCoya Therapeutics, Inc. (COYA)
Form Type8-K
Filed DateJun 26, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

TL;DR

Coya Therapeutics held a shareholder vote, details to follow.

AI Summary

Coya Therapeutics, Inc. filed an 8-K on June 26, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or the outcomes, but it serves as a notification of these events.

Why It Matters

This filing indicates that Coya Therapeutics held a shareholder vote, which could have implications for corporate governance and future strategic decisions.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose any new financial information or significant operational changes.

Key Players & Entities

  • Coya Therapeutics, Inc. (company) — Registrant
  • June 26, 2025 (date) — Date of earliest event reported

FAQ

What specific matters were submitted for a vote by Coya Therapeutics' security holders?

The filing does not specify the exact matters submitted for a vote, only that such matters were presented.

When did the event requiring this 8-K filing occur?

The earliest event reported occurred on June 26, 2025.

What is Coya Therapeutics' principal executive office address?

The address is 5850 San Felipe St., Suite 500, Houston, Texas 77057.

What is Coya Therapeutics' telephone number?

The telephone number is (800) 587-8170.

What is Coya Therapeutics' fiscal year end?

The fiscal year end is December 31.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 26, 2025 regarding Coya Therapeutics, Inc. (COYA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.